FDA approved Alzheimer’s drug because trial data showed it was ‘reasonably likely’ to help patients
[ad_1] The U.S Food and Drug Administration (FDA) defended its controversial decision to approve the first new Alzheimer’s drug since 2003 this week. Aducanumab, which… Read More »FDA approved Alzheimer’s drug because trial data showed it was ‘reasonably likely’ to help patients